Kim Newton - Senior Scientist, Physiological Chemistry

Kim Newton

Senior Scientist, Physiological Chemistry

17
Years at Genentech
40
Publications
2
Awards & Honors

I joined Genentech in 2001 as a postdoc after completing my PhD in the cell death lab of Andreas Strasser at the Walter & Eliza Hall Institute in Australia. As a postdoc with Vishva Dixit, I worked on several projects including the role of the adaptor protein CARMA1/CARD11 in lymphocyte development and activation, the effect of TNF family ligands EDA-A1 and EDA-A2 on hair, sweat gland and muscle homeostasis, and the characterization of a kinase called RIPK3, which turned out to be a key effector of a regulated form of necrotic cell death termed necroptosis. These diverse projects were developed in collaboration with several departments and I saw first hand how much can be achieved when experts across disciplines pull together. Enthusiastic, talented colleagues combined with exciting, medically relevant science made staying on as a scientist an easy decision.

The current mission of my group is to decipher the signaling mechanisms unleashing proinflammatory cell death programs that may exacerbate a range of inflammatory diseases. Our goal is to unveil novel therapeutics targets with the potential to benefit patients.

Featured Publication

RIPK1 inhibits ZBP1-driven necroptosis during development.

Nature. 2016 Dec 1;540(7631):129-133.

Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, Ngu H, Webster JD, Dixit VM.